Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Kramer

Showing results (41-50 of 104) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapyBrian H Kushner, Samuel D J Yeh, Kim Kramer, et al.
Pediatric Blood & Cancer|June 24, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With NeuroblastomaWei Wei, Maggie Eidson Fader, Brian H Kushner, et al.
Cancer|May 2, 2013
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibodyBrian H Kushner, Shakeel Modak, Ellen M Basu, et al.
Cancer|September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literatureBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2Matthias Miederer, Michael R McDevitt, Paul Borchardt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2010
Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluidPing He, Kim Kramer, Peter Smith-Jones, et al.
Journal of Neuro-Oncology|March 18, 2019
Targeted radioimmunotherapy for embryonal tumor with multilayered rosettesKayleen Bailey, Neeta Pandit-Taskar, John L Humm, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2023
Radioimmunoscintigraphy and Pretreatment Dosimetry of <sup>131</sup>I-Omburtamab for Planning Treatment of Leptomeningeal DiseaseNeeta Pandit-Taskar, Milan Grkovski, Pat B Zanzonico, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionNai-Kong V Cheung, Irene Y Cheung, Brian H Kushner, et al.
Oncoimmunology|July 4, 2015
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II studyBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
Pageof 11

Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapyBrian H Kushner, Samuel D J Yeh, Kim Kramer, et al.
Pediatric Blood & Cancer|June 24, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With NeuroblastomaWei Wei, Maggie Eidson Fader, Brian H Kushner, et al.
Cancer|May 2, 2013
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibodyBrian H Kushner, Shakeel Modak, Ellen M Basu, et al.
Cancer|September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literatureBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2Matthias Miederer, Michael R McDevitt, Paul Borchardt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2010
Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluidPing He, Kim Kramer, Peter Smith-Jones, et al.
Journal of Neuro-Oncology|March 18, 2019
Targeted radioimmunotherapy for embryonal tumor with multilayered rosettesKayleen Bailey, Neeta Pandit-Taskar, John L Humm, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2023
Radioimmunoscintigraphy and Pretreatment Dosimetry of <sup>131</sup>I-Omburtamab for Planning Treatment of Leptomeningeal DiseaseNeeta Pandit-Taskar, Milan Grkovski, Pat B Zanzonico, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionNai-Kong V Cheung, Irene Y Cheung, Brian H Kushner, et al.
Oncoimmunology|July 4, 2015
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II studyBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
Pageof 11